Highlights Corcept Therapeutics Incorporated

Stocks

CORT

US2183521028

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 12:03:46 2026-06-11 pm EDT			5-day change	1st Jan Change
81.96 ^USD	+4.91%		+10.12%	+136.98%

Jun. 06	Corcept Therapeutics Incorporated Presents New Data from Catalyst and Momentum Trials At American Diabetes Association?s 86Th Scientific Sessions	CI
Jun. 04	Corcept Therapeutics Insider Sold Shares Worth $1,412,000, According to a Recent SEC Filing	MT

Highlights

Jun. 06	Corcept Therapeutics Incorporated Presents New Data from Catalyst and Momentum Trials At American Diabetes Association?s 86Th Scientific Sessions	CI
May. 29	Corcept Therapeutics Incorporated Presents New Data From Pivotal Phase 3 ROSELLA Trial Of Lifyorli Plus Nab-Paclitaxel At ASCO 2026	CI
May. 27	Corcept to resubmit NDA for relacorilant as treatment for Cushing's syndrome patients	RE
May. 27	Corcept Therapeutics Incorporated Resubmits New Drug Application for Relacorilant as Treatment for Patients with Cushing?S Syndrome	CI
Apr. 30	Corcept Therapeutics Q1 Swings to Loss, Revenue Rises; Raises Full-Year Guidance	MT
Apr. 30	Earnings Flash (CORT) Corcept Therapeutics Posts Q1 Per Share Loss $-0.30	MT
Apr. 30	(CORT) Corcept Therapeutics Expects 2026 Revenue Range $950M-$1.05B, vs. FactSet Est of $899.5M	MT
Apr. 30	Earnings Flash (CORT) Corcept Therapeutics Incorporated Reports Q1 Revenue $164.9M, vs. FactSet Est of $185.8M	MT
Apr. 30	Corcept Therapeutics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 30	Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis	CI
Apr. 30	Corcept Therapeutics Incorporated Raises Earnings Guidance for 2026	CI
Apr. 21	Corcept Therapeutics Presents New Data From Pivotal Phase 3 ROSELLA Trial Of Lifyorli Plus Nab-Paclitaxel In Platinum-Resistant Ovarian Cancer	CI
Apr. 10	Corcept Therapeutics Incorporated Presents Final Overall Survival Data from Its Pivotal Phase 3 Rosella Trial of Lifyorli?	CI
Mar. 28	Corcept Therapeutics Incorporated Presents Data From Momentum Trial At American College Of Cardiology Annual Scientific Session	CI
Mar. 25	Corcept Therapeutics Incorporated Receives FDA Approval For Lifyorli (Relacorilant) Plus Nab-Paclitaxel For Platinum-Resistant Ovarian Cancer	CI
Mar. 25	Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer	RE
Mar. 25	US FDA approves Corcept Therapeutics' drug for hard-to-treat ovarian cancer	RE
Feb. 24	Corcept Therapeutics Q4 Earnings Fall, Revenue Rises	MT
Feb. 24	Tranche Update on Corcept Therapeutics Incorporated's Equity Buyback Plan announced on January 8, 2024.	CI
Feb. 24	Corcept Therapeutics Incorporated Provides Revenue Guidance for the Full Year 2026	CI
Feb. 24	Corcept Therapeutics Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Feb. 20	Corcept Therapeutics Loses Cushing's Syndrome Patent Case Against Teva	MT
Jan. 22	Corcept Therapeutics Incorporated Announces Overall Survival Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer	CI
Jan. 22	Corcept's cancer drug cuts risk of death in ovarian cancer trial	RE
Dec. 31	Corcept receives Complete Response Letter for relacorilant as a treatment for patients with hypercortisolism	RE